Csaba Szabo Selected Research

Investigational Therapies (Experimental Therapy)

1/2022	Effects of the PARP Inhibitor Olaparib on the Response of Human Peripheral Blood Leukocytes to Bacterial Challenge or Oxidative Stress.
1/2020	Effects of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Cerulein-Induced Pancreatitis.
1/2019	The PARP inhibitor olaparib exerts beneficial effects in mice subjected to cecal ligature and puncture and in cells subjected to oxidative stress without impairing DNA integrity: A potential opportunity for repurposing a clinically used oncological drug for the experimental therapy of sepsis.
11/2016	Screening of a composite library of clinically used drugs and well-characterized pharmacological compounds for cystathionine β-synthase inhibition identifies benserazide as a drug potentially suitable for repurposing for the experimental therapy of colon cancer.
3/2016	Gasotransmitters in cancer: from pathophysiology to experimental therapy.
1/2015	Time-Dependent and Organ-Specific Changes in Mitochondrial Function, Mitochondrial DNA Integrity, Oxidative Stress and Mononuclear Cell Infiltration in a Mouse Model of Burn Injury.
4/2014	Regulation of mitochondrial bioenergetic function by hydrogen sulfide. Part II. Pathophysiological and therapeutic aspects.
9/2002	The Flagellin-TLR5 Axis: Therapeutic Opportunities.
5/2002	PARP as a Drug Target for the Therapy of Diabetic Cardiovascular Dysfunction.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Csaba Szabo Research Topics

Disease

31	Inflammation (Inflammations) 01/2021 - 05/2002
28	Neoplasms (Cancer) 01/2022 - 09/2005
23	Burns 01/2019 - 07/2003
19	Sepsis (Septicemia) 01/2022 - 09/2002
16	Reperfusion Injury 10/2018 - 02/2002
14	Colonic Neoplasms (Colon Cancer) 01/2021 - 07/2013
13	Ischemia 01/2021 - 08/2003
12	Acute Lung Injury 11/2020 - 08/2003
11	Septic Shock (Toxic Shock Syndrome) 01/2022 - 04/2003
11	Critical Illness (Critically Ill) 01/2020 - 04/2003
9	Necrosis 01/2018 - 05/2008
9	Lung Injury 09/2017 - 12/2002
9	Smoke Inhalation Injury 08/2011 - 07/2003
8	Infarction (Infarctions) 12/2017 - 02/2002
8	Myocardial Ischemia (Ischemic Heart Diseases) 07/2014 - 02/2002
7	Mitochondrial Diseases (Mitochondrial Disease) 01/2021 - 03/2012
6	Infections 01/2021 - 09/2002
5	Hypoxia (Hypoxemia) 11/2020 - 04/2008
5	Atherosclerosis 01/2019 - 07/2008
5	Colorectal Neoplasms (Colorectal Cancer) 11/2017 - 04/2014
5	Diabetes Mellitus 01/2017 - 05/2002
5	Shock 03/2013 - 09/2002
5	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 04/2012 - 09/2002
4	Down Syndrome (Down's Syndrome) 01/2022 - 01/2020
4	Hyperglycemia 12/2017 - 08/2011
4	Myocardial Infarction 12/2017 - 02/2002
4	Endotoxemia 02/2017 - 11/2006
4	Pulmonary Edema 02/2011 - 04/2008
4	Stroke (Strokes) 11/2009 - 12/2006
3	Multiple Organ Failure (MODS) 12/2021 - 05/2009
3	Hypercholesterolemia 10/2018 - 12/2017
3	Hemorrhage 10/2018 - 06/2008
3	Wounds and Injuries (Trauma) 10/2018 - 02/2016
3	Cardiovascular Diseases (Cardiovascular Disease) 12/2017 - 12/2006
3	Ovarian Neoplasms (Ovarian Cancer) 01/2017 - 12/2013
3	Edema (Dropsy) 10/2011 - 12/2002
2	Obesity 01/2022 - 01/2018
2	Glioma (Gliomas) 01/2022 - 09/2005
2	Body Weight (Weight, Body) 01/2022 - 10/2018

Drug/Important Bio-Agent (IBA)

36	EnzymesIBA 01/2022 - 04/2003
35	Hydrogen Sulfide (Sulfide, Hydrogen)IBA 01/2022 - 09/2007
22	CystathionineIBA 01/2022 - 08/2011
16	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2022 - 04/2003
14	Poly(ADP-ribose) Polymerase InhibitorsIBA 12/2021 - 04/2003
12	SmokeIBA 10/2018 - 07/2003
11	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2005
11	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2018 - 05/2002
10	3-mercaptopyruvate sulphurtransferaseIBA 01/2022 - 02/2015
10	LyasesIBA 01/2021 - 08/2011
10	Peroxidase (Myeloperoxidase)IBA 01/2020 - 06/2004
10	salicylhydroxamic acid (SHAM)IBA 10/2018 - 04/2008
9	Oxygen (Dioxygen)IBA 11/2020 - 11/2006
8	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 05/2002
8	NitrogenIBA 01/2019 - 07/2008
8	Poly Adenosine Diphosphate RiboseIBA 01/2015 - 02/2002
7	Adenosine Triphosphate (ATP)IBA 01/2021 - 11/2006
7	Ligases (Synthetase)IBA 01/2021 - 02/2002
7	Oxidants (Oxidizing Agents)IBA 01/2016 - 05/2002
6	olaparibIBA 01/2022 - 01/2017
6	Mitochondrial DNA (mtDNA)IBA 01/2021 - 10/2010
6	Pharmaceutical PreparationsIBA 12/2020 - 03/2005
6	CytokinesIBA 11/2016 - 01/2005
6	Peroxynitrous Acid (Peroxynitrite)IBA 02/2011 - 07/2003
6	INO 1001IBA 05/2010 - 08/2003
5	Sulfides (Thioethers)IBA 01/2022 - 05/2008
5	Aminooxyacetic AcidIBA 01/2021 - 07/2013
5	GasotransmittersIBA 01/2021 - 03/2013
5	CreatinineIBA 01/2019 - 01/2016
5	LipopolysaccharidesIBA 02/2017 - 04/2003
5	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2016 - 08/2011
5	N- (oxo- 5,6- dihydrophenanthridin- 2- yl)- N,N- dimethylacetamide hydrochlorideIBA 06/2008 - 02/2002
4	HMGB1 Protein (HMG1)IBA 01/2021 - 09/2009
4	Malondialdehyde (Propanedial)IBA 01/2020 - 01/2015
4	Cystathionine beta-Synthase (Serine Sulfhydrase)IBA 01/2020 - 01/2016
4	Urea (Carbamide)FDA LinkGeneric 01/2019 - 01/2016
4	3-nitrotyrosineIBA 12/2017 - 08/2003
4	Reactive Nitrogen SpeciesIBA 02/2011 - 07/2003
3	Mitochondrial Proteins (Mitochondrial Protein)IBA 01/2022 - 03/2013
3	Biomarkers (Surrogate Marker)IBA 01/2022 - 12/2013
3	Interleukin-6 (Interleukin 6)IBA 12/2021 - 05/2012
3	Messenger RNA (mRNA)IBA 01/2021 - 10/2010
3	ProdrugsIBA 01/2021 - 08/2012
3	Phosphotransferases (Kinase)IBA 02/2020 - 10/2011
3	Amylases FDA Link 01/2020 - 11/2016
3	Biological ProductsIBA 01/2020 - 03/2010
3	GYY 4137IBA 10/2018 - 05/2015
3	Nitric Oxide Synthase (NO Synthase)IBA 10/2017 - 05/2009
3	Free RadicalsIBA 11/2015 - 05/2002
3	ChemokinesIBA 05/2015 - 04/2008
3	AntioxidantsIBA 02/2015 - 04/2003
3	Evans Blue (Blue, Evans)FDA Link 05/2010 - 05/2008
3	Nitric Oxide Synthase Type I (Neuronal Nitric Oxide Synthase)IBA 03/2010 - 04/2008
3	EndotoxinsIBA 10/2003 - 12/2002

Therapy/Procedure

21	Therapeutics 01/2022 - 03/2005
9	Investigational Therapies (Experimental Therapy) 01/2022 - 05/2002
8	Ligation 01/2019 - 08/2003
5	Punctures 01/2019 - 03/2013
4	Critical Care (Surgical Intensive Care) 10/2018 - 03/2009
4	Anesthesia 04/2012 - 01/2009
3	Resuscitation 10/2018 - 03/2009